Pfizer's Viagra market share in China challenged by Guangzhou Baiyunshan's 'golden spear'

Jin'ge (Chinese for "golden spear") from China's Guangzhou Baiyunshan is said to be on track to eclipse sales of Pfizer's ($PFE) Viagra in China in a few years with a price that is 60% less than the branded erectile dysfunction drug. The company is also said to be looking at taking the copy international. Before Jin'ge hit the market last year, Viagra reportedly had 60% of the market share and Eli Lilly's ($LLY) Cialis held 34.6%, FiercePharmaAsia reports.

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.